Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Libutti Website

Steven K. Libutti, M.D.

Selected Publications
1)  Blansfield JA, Caragacianu D, Alexander HR, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK.
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Clin. Cancer Res. 14: 270-80, 2008. [Journal]
2)  Chung J, Braunschweig T, Williams R, Guerrero N, Hoffmann KM, Kwon M, Song YK, Libutti SK, Hewitt SM.
Factors in Tissue Handling and Processing That Impact RNA Obtained From Formalin-fixed, Paraffin-embedded Tissue.
J. Histochem. Cytochem. Epub ahead of print, 2008. [Journal]
3)  Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, Wesley R, Carrasquillo JA.
Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the.
Nucl. Med. Biol. 35: 441-5, 2008. [Journal]
4)  Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA.
Identification of genes differentially expressed in benign versus malignant thyroid tumors.
Clin. Cancer Res. 14: 3327-37, 2008. [Journal]
5)  Lodish MB, Powell AC, Abu-Asab M, Cochran C, Lenz P, Libutti SK, Pingpank JF, Tsokos M, Gorden P.
Insulinoma and gastrinoma syndromes from a single intrapancreatic neuroendocrine tumor.
J. Clin. Endocrinol. Metab. 93: 1123-8, 2008. [Journal]
6)  Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL.
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Cancer Chemother. Pharmacol. 62: 647-53, 2008. [Journal]
7)  Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR, Pingpank JF, Keil M, Bartlett DL, Libutti SK.
Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia.
Surgery. 143: 750-8, 2008. [Journal]
8)  Shen HC, Rosen JE, Yang LM, Savage SA, Burns AL, Mateo CM, Agarwal SK, Chandrasekharappa SC, Spiegel AM, Collins FS, Marx SJ, Libutti SK.
Parathyroid tumor development involves deregulation of homeobox genes.
Endocr. Relat. Cancer. 15: 267-75, 2008. [Journal]
9)  Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, Marx SJ, Gibril F, Jensen RT.
Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.
Ann. Surg. 247: 501-10, 2008. [Journal]
10)  Henry LR, Solomon NP, Howard R, Gurevich-Uvena J, Horst LB, Coppit G, Orlikoff R, Libutti SK, Shaha AR, Stojadinovic A.
The functional impact on voice of sternothyroid muscle division during thyroidectomy.
Ann. Surg. Oncol. 15: 2027-33, 2008. [Journal]
11)  He M, Rosen J, Mangiameli D, Libutti SK.
Cancer development and progression.
Adv. Exp. Med. Biol. 593: 117-33, 2007. [Journal]
12)  Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK.
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).
Surgery. 142: 814-8; discussion 818.e1-2, 2007. [Journal]
13)  Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI, Libutti SK.
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Journal of translational medicine. 5: 38, 2007. [Journal]
14)  Rodriguez-Canales J, Hanson J, Tangrea M, Erickson H, Albert P, Wallis B, Richardson A, Pinto P, Linehan W, Gillespie J, Merino M, Libutti S, Woodson K, Emmert-Buck M, Chuaqui R.
Identification of a unique epigenetic sub-microenvironment in prostate cancer.
J Pathol. 211: 410-9, 2007. [Journal]
15)  Teo BK, Seo Y, Bacharach SL, Carrasquillo JA, Libutti SK, Shukla H, Hasegawa BH, Hawkins RA, Franc BL.
Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data.
J. Nucl. Med. 48: 802-10, 2007. [Journal]
16)  Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, Bur M, Poff J, Xie J, Libutti SK, Li KC, Wood BJ.
Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.
Clin. Cancer Res. 13: 2722-7, 2007. [Journal]
17)  Kwon M, Libutti SK.
Advances in understanding angiogenesis through molecular studies.
Int J Radiat Oncol Biol Phys. 64: 26-32, 2006. [Journal]
18)  Tang JS, Choy G, Bernardo M, Thomasson D, Libutti SK, Choyke PL.
Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model.
Investigative radiology. 41: 691-6, 2006. [Journal]
19)  Libutti SK, Alexander HR.
Gastrinoma: sporadic and familial disease.
Surg. Oncol. Clin. N. Am. 15: 479-96, 2006. [Journal]
20)  Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG.
Gene promoter methylation in prostate tumor-associated stromal cells.
J Natl Cancer Inst. 98: 255-61, 2006. [Journal]
21)  Sudheendra D, Neeman Z, Kam A, Locklin J, Libutti SK, Wood BJ.
Intermittent Hepatic Vein Balloon Occlusion During Radiofrequency Ablation in the Liver.
Cardiovasc Intervent Radiol. 2006. [Journal]
22)  Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ.
Islet cell tumors.
Current problems in surgery. 43: 685-765, 2006. [Journal]
23)  Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, Spiegel AM.
Parathyroid-specific double knockout of Gq- and G11-{alpha} subunits leads to a phenotype resembling germline knockout of the extracellular Ca++-sensing receptor.
Mol Endocrinol. 2006. [Journal]
24)  Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R.
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.
BMC Cancer. 6: 131, 2006. [Journal]
25)  Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JC, Chuaqui RF, Gillespie JW, Erickson HS, Bonner RF, Pohida TJ, Emmert-Buck MR, Libutti SK.
Tumor-Associated Endothelial Cells Display GSTP1 and RARbeta2 Promoter Methylation in Human Prostate Cancer.
J Transl Med. 4: 13, 2006. [Journal]
26)  Grover AC, Skarulis M, Alexander HR, Pingpank JF, Javor ED, Chang R, Shawker T, Gorden P, Cochran C, Libutti SK.
A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas.
Surgery. 138: 1003-8, 2005. [Journal]
27)  Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK.
A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.
Surgery. 138: 1050-7, 2005. [Journal]
28)  Tandle AT, Mazzanti C, Alexander HR, Roberts DD, Libutti SK.
Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.
Cytokine. 30: 347-58, 2005. [Journal]
29)  Rosen JE, Costouros NG, Lorang D, Burns AL, Alexander HR, Skarulis MC, Cochran C, Pingpank JF, Marx SJ, Spiegel AM, Libutti SK.
Gland size is associated with changes in gene expression profiles in sporadic parathyroid adenomas.
Ann. Surg. Oncol. 12: 412-6, 2005. [Journal]
30)  Alexander HR, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T.
Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
Ann Surg Oncol. 12: 138-44, 2005. [Journal]
31)  Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, Alexander HR.
Limited Survival in Patients With Carcinomatosis From Foregut Malignancies After Cytoreduction and Continuous Hyperthermic Peritoneal Perfusion.
J Gastrointest Surg. 9: 1346-1353, 2005. [Journal]
32)  Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden P.
Malignant insulinoma: spectrum of unusual clinical features.
Cancer. 104: 264-72, 2005. [Journal]
33)  Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa SC, Burns AL, Collins FS, Spiegel AM, Marx SJ.
Menin molecular interactions: insights into normal functions and tumorigenesis.
Horm Metab Res. 37: 369-74, 2005. [Journal]
34)  Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR.
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.
J. Clin. Oncol. 23: 3465-74, 2005. [Journal]
35)  Libutti SK.
Understanding the role of gender in the incidence of thyroid cancer.
Cancer J. 11: 104-5, 2005. [Journal]
36)  Miller WJ, Kayton ML, Patton A, O'Connor S, He M, Vu H, Baibakov G, Lorang D, Knezevic V, Kohn E, Alexander HR, Stirling D, Payvandi F, Muller GW, Libutti SK.
A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assayChorioallantoic Membrane (CAM) Assay.
J Transl Med. 2: 4, 2004. [Journal]
37)  Tandle A, Blazer DG, Libutti SK.
Antiangiogenic gene therapy of cancer: recent developments.
J Transl Med. 2: 22, 2004. [Journal]
38)  Libutti SK.
Do angiogenesis inhibitors perform a physiologic gatekeeper role in cancer prevention?.
Cancer J. 10: 12-4, 2004. [Journal]
39)  Mazzanti CM, Tandle A, Lorang D, Costouros N, Roberts D, Bevilacqua G, Libutti SK.
Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells.
Genome Res. 14: 1585-93, 2004. [Journal]
40)  Bourdeau I, Antonini SR, Lacroix A, Kirschner LS, Matyakhina L, Lorang D, Libutti SK, Stratakis CA.
Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators.
Oncogene. 23: 1575-85, 2004. [Journal]
41)  Minn AH, Kayton M, Lorang D, Hoffmann SC, Harlan DM, Libutti SK, Shalev A.
Insulinomas and expression of an insulin splice variant.
Lancet. 363: 363-7, 2004. [Journal]
42)  Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR.
Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms.
Surgery. 136: 1176-82, 2004. [Journal]
43)  Feldman AL, Stetler-Stevenson WG, Costouros NG, Knezevic V, Baibakov G, Alexander HR, Lorang D, Hewitt SM, Seo DW, Miller MS, O'Connor S, Libutti SK.
Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism.
Cancer Res. 64: 4481-6, 2004. [Journal]
44)  Agarwal SK, Lee Burns A, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB, Mullendore ME, Whitten I, Skarulis MC, Simonds WF, Mateo C, Crabtree JS, Scacheri PC, Ji Y, Novotny EA, Garrett-Beal L, Ward JM, Libutti SK, Richard Alexander H, Cerrato A, Parisi MJ, Santa Anna-A S, Oliver B, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ.
Molecular pathology of the MEN1 gene.
Ann N Y Acad Sci. 1014: 189-98, 2004. [Journal]
45)  McCart JA, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, Deng H, Miller M, Xu H, Libutti SK, Alexander HR, Bartlett DL.
Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using (111)In-Pentetreotide.
Mol Ther. 10: 553-61, 2004. [Journal]
46)  Martínez A, Zudaire E, Portal-Núñez S, Guédez L, Libutti SK, Stetler-Stevenson WG, Cuttitta F.
Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth.
Cancer Res. 64: 6489-94, 2004. [Journal]
47)  Friedman M, Mikityansky I, Kam A, Libutti SK, Walther MM, Neeman Z, Locklin JK, Wood BJ.
Radiofrequency ablation of cancer.
Cardiovasc Intervent Radiol. 27: 427-34, 2004. [Journal]
48)  McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK.
Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring.
J Immunother. 27: 161-175, 2004. [Journal]
49)  Sundaram SK, Freedman NM, Carrasquillo JA, Carson JM, Whatley M, Libutti SK, Sellers D, Bacharach SL.
Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
J Nucl Med. 45: 1328-33, 2004. [Journal]
50)  Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR.
Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion.
J Gastrointest Surg. 8: 200-7, 2004. [Journal]
51)  Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK, Costourous N.
Using Gene Expression Profiling to Differentiate Benign versus Malignant Thyroid Tumors.
Cancer Res. 64: 2898-903, 2004. [Journal]
52)  Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR.
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
J Clin Oncol. 21: 4560-7, 2003. [Journal]
53)  Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK, Roberts DD.
Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin.
Cancer Res. 63: 6405-12, 2003. [Journal]
54)  Tandle A, Libutti SK.
Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Clin Adv Hematol Oncol. 1: 41-8, 2003. [Journal]
55)  Choy G, O'Connor S, Diehn FE, Costouros N, Alexander HR, Choyke P, Libutti SK.
Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging.
Biotechniques. 35: 1022-6, 1028-30, 2003. [Journal]
56)  Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, Whatley M, Carson JM, Sellers D, Libutti SK, Yang JC, Bacharach SL.
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.
Eur J Nucl Med Mol Imaging. 30: 46-53, 2003. [Journal]
57)  Choy G, Choyke P, Libutti SK.
Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research.
Mol Imaging. 2: 303-12, 2003. [Journal]
58)  Alexander HR, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T.
Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver.
Clin Cancer Res. 9: 6343-9, 2003. [Journal]
59)  Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT, Alexander HR.
Management and outcome of patients with sporadic gastrinoma arising in the duodenum.
Ann Surg. 238: 42-8, 2003. [Journal]
60)  Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O'Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM.
Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism.
Cancer Res. 63: 8022-8, 2003. [Journal]
61)  Kayton ML, Costouros NG, Lorang D, Alexander HR, Hewitt SM, Cochran C, Shalev A, Harlan D, Skarulis MC, Gorden P, Libutti SK.
Peak stimulated insulin secretion is associated with specific changes in gene expression profiles in sporadic insulinomas.
Surgery. 134: 982-7; discussion 987-8, 2003. [Journal]
62)  Neeman Z, Libutti SK, Patti JW, Wood BJ.
Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis.
Clin Imaging. 27: 417-20, 2003. [Journal]
63)  Chan TJ, Libutti SK, McCart JA, Chen C, Khan A, Skarulis MK, Weinstein LS, Doppman JL, Marx SJ, Alexander HR.
Persistent Primary Hyperparathyroidism Caused by Adenomas Identified in Pharyngeal or Adjacent Structures.
World J Surg. 2003. [Journal]
64)  Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC.
Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
J Cell Physiol. 197: 139-48, 2003. [Journal]
65)  Elaraj DM, Skarulis MC, Libutti SK, Norton JA, Bartlett DL, Pingpank JF, Gibril F, Weinstein LS, Jensen RT, Marx SJ, Alexander HR.
Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1.
Surgery. 134: 858-64, 2003. [Journal]
66)  Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, Merino MJ, Schrump DS, Libutti SK, Alexander HR, Sarlis NJ.
Role of metastasectomy in the management of thyroid carcinoma: the NIH experience.
J Surg Oncol. 82: 10-8, 2003. [Journal]
67)  Hwang JJ, Uchio EM, Pavlovich CP, Pautler SE, Libutti SK, Linehan WM, Walther MM.
Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach.
J Urol. 169: 895-8, 2003. [Journal]
68)  Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL.
Using Positron Emission Tomography 2-Deoxy-2-[18F]Fluoro-D-Glucose, 11CO, and 15O-Water for Monitoring Androgen Independent Prostate Cancer.
Mol Imaging Biol. 5: 86-93, 2003. [Journal]
69)  Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH.
von Hippel-Lindau disease.
Lancet. 361: 2059-67, 2003. [Journal]
70)  Calvo A, Feldman AL, Libutti SK, Green JE.
Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice.
Cancer Res. 62: 3934-3938, 2002. [Journal]
71)  Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander HR, Libutti SK.
Advantages of mRNA amplification for microarray analysis.
Biotechniques. 33: 906-12, 914, 2002. [Journal]
72)  Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A, Chang R, Shawker T, Skarulis MC, Gorden P.
Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure.
J Am Coll Surg. 194: 761-4, 2002. [Journal]
73)  Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET.
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
Breast Cancer Res. 4: R3, 2002. [Journal]
74)  Alexander HR, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, Beresnev T.
Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
Cancer. 95: 730-6, 2002. [Journal]
75)  Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR, Chen CC, Chang R, Chandrasekharappa SC, Collins FS.
Hyperparathyroidism in hereditary syndromes: special expressions and special managements.
J Bone Miner Res. 17 Suppl 2: N37-43, 2002. [Journal]
76)  Lans TE, ten Hagen TL, van Horssen R, Wu PC, van Tiel ST, Libutti SK, Alexander HR, Eggermont AM.
Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
Ann Surg Oncol. 9: 812-9, 2002. [Journal]
77)  Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, Gnant MF, Alexander HR.
Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF.
Blood. 100: 1334-9, 2002. [Journal]
78)  Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE.
Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.
Int J Cancer. 101: 224-34, 2002. [Journal]
79)  Pautler SE, Richards C, Libutti SK, Linehan WM, Walther MM.
Intentional resection of the diaphragm during cytoreductive laparoscopic radical nephrectomy.
J Urol. 167: 48-50, 2002. [Journal]
80)  Yu J, Steiner FA, Muench JP, Gourgiotis L, Skarulis MC, Altemus RM, Libutti SK, Merino MJ, Sarlis NJ.
Juxtathyroidal neck soft tissue angiosarcoma presenting as an undifferentiated thyroid carcinoma.
Thyroid. 12: 427-32, 2002. [Journal]
81)  Costouros NG, Lorang D, Zhang Y, Miller MS, Diehn FE, Hewitt SM, Knopp MV, Li KC, Choyke PL, Alexander HR, Libutti SK.
Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI.
Mol Imaging. 1: 301-8, 2002. [Journal]
82)  Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK.
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
Biotechniques. 33: 664-666, 2002. [Journal]
83)  Costouros NG, Libutti SK.
Microarray technology and gene expression analysis for the study of angiogenesis.
Expert Opin Biol Ther. 2: 545-556, 2002. [Journal]
84)  Costouros NG, Diehn FE, Libutti SK.
Molecular imaging of tumor angiogenesis.
J Cell Biochem Suppl. 39: 72-8, 2002. [Journal]
85)  Marcos HB, Libutti SK, Alexander HR, Lubensky IA, Bartlett DL, Walther MM, Linehan WM, Glenn GM, Choyke PL.
Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison.
Radiology. 225: 751-8, 2002. [Journal]
86)  Diehn FE, Costouros NG, Miller MS, Feldman AL, Alexander HR, Li KC, Libutti SK.
Noninvasive fluorescent imaging reliably estimates biomass in vivo.
Biotechniques. 33: 1250-2, 1254-5, 2002. [Journal]
87)  Wood BJ, Ramkaransingh JR, Fojo T, Walther MM, Libutti SK.
Percutaneous tumor ablation with radiofrequency.
Cancer. 94: 443-51, 2002. [Journal]
88)  Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK.
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
Cancer. 95: 1637-43, 2002. [Journal]
89)  Albright SV, McCart JA, Libutti SK, Bartlett DL, Alexander HR, Sampson ML, Ruddel ME, Remaley AT.
Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma.
Ann Clin Biochem. 39: 513-5, 2002. [Journal]
90)  Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR.
Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts.
Int J Cancer. 99: 149-53, 2002. [Journal]
91)  Choyke PL, Knopp MV, Libutti SK.
Special techniques for imaging blood flow to tumors.
Cancer J. 8: 109-118, 2002. [Journal]
92)  Gourgiotis L, Al-Zubaidi N, Skarulis MC, Papanicolaou DA, Libutti SK, Alexander HR, Merino MJ, Sarlis NJ.
Successful outcome after surgical management in two cases of the.
Endocr Pract. 8: 259-65, 2002. [Journal]
93)  Elaraj DM, Remaley AT, Simonds WF, Skarulis MC, Libutti SK, Bartlett DL, Venzon DJ, Marx SJ, Alexander HR.
Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism.
Surgery. 132: 1028-33; discussion 1033-4, 2002. [Journal]
94)  Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS.
A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors.
Proc Natl Acad Sci U S A. 98: 1118-1123, 2001. [Journal]
95)  Feldman AL, Alexander HR, Bartlett DL, Kranda KC, Miller MS, Costouros NG, Choyke PL, Libutti SK.
A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases.
Ann Surg Oncol. 8: 741-5, 2001. [Journal]
96)  Libutti SK, Alexander HR, Choyke P, Bartlett DL, Bacharach SL, Whatley M, Jousse F, Eckelman WC, Kranda K, Neumann RD, Carrasquillo JA.
A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels.
Ann Surg Oncol. 8: 779-786, 2001. [Journal]
97)  Feldman AL, Alexander HR, Hewitt SM, Lorang D, Thiruvathukal CE, Turner EM, Libutti SK.
Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors.
J Natl Cancer Inst. 93: 1014-1020, 2001. [Journal]
98)  Kayton ML, Libutti SK.
Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Curr Opin Investig Drugs. 2: 136-8, 2001. [Journal]
99)  Zogakis TG, Bartlett DL, Libutti SK, Liewehr DJ, Steinberg SM, Fraker DL, Alexander HR.
Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Ann Surg Oncol. 8: 771-8, 2001. [Journal]
100)  Zogakis TG, Libutti SK.
General aspects of anti-angiogenesis and cancer therapy.
Expert Opin Biol Ther. 1: 253-75, 2001. [Journal]
101)  Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR.
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Surgery. 129: 176-87, 2001. [Journal]
102)  Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, Bartlett DL.
Laparoscopic continuous hyperthermic peritoneal perfusion.
J Am Coll Surg. 193: 225-9, 2001. [Journal]
103)  Riddell C, Carson RE, Carrasquillo JA, Libutti SK, Danforth DN, Whatley M, Bacharach SL.
Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment.
J Nucl Med. 42: 1316-23, 2001. [Journal]
104)  Watabe H, Channing MA, Riddell C, Jousse F, Libutti SK, Carrasquillo JA, Bacharach SL, Carson RE.
Noninvasive estimation of the aorta input function for measurement of tumor blood flow with.
IEEE Trans Med Imaging. 20: 164-74, 2001. [Journal]
105)  Berger AC, Gibril F, Venzon DJ, Doppman JL, Norton JA, Bartlett DL, Libutti SK, Jensen RT, Alexander HR.
Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome.
J Clin Oncol. 19: 3051-7, 2001. [Journal]
106)  Kivlen MH, Bartlett DL, Libutti SK, Skarulis MC, Marx SJ, Simonds WF, Weinstein LS, Jensen RT, McCart JA, Naik AM, Kranda KC, Brennan MF, Norton JA, Fraker DL, Alexander HR.
Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1.
Surgery. 130: 991-8, 2001. [Journal]
107)  Lans TE, Bartlett DL, Libutti SK, Gnant MF, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR.
Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.
Clin Cancer Res. 7: 784-90, 2001. [Journal]
108)  Feldman AL, Pak H, Yang JC, Alexander HR, Libutti SK.
Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Cancer. 91: 1525-9, 2001. [Journal]
109)  McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL.
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
Cancer Res. 61: 8751-7, 2001. [Journal]
110)  Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W.
8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide.
Clin Positron Imaging. 3: 144, 2000. [Journal]
111)  Walther MC, Shawker TH, Libutti SK, Lubensky I, Choyke PL, Venzon D, Linehan WM.
A phase 2 study of radio frequency interstitial tissue ablation of localized renal tumors.
J Urol. 163: 1424-7, 2000. [Journal]
112)  Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC.
A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Clin Cancer Res. 6: 3062-70, 2000. [Journal]
113)  Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK.
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.
Cancer Res. 60: 1503-1506, 2000. [Journal]
114)  Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, Lubensky I, McKee SA, Maher ER, Linehan WM, Walther MM.
Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease.
Surgery. 128: 1022-7;discussion 1027-8, 2000. [Journal]
115)  McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR, Bartlett DL.
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
Gene Ther. 7: 1217-23, 2000. [Journal]
116)  Alexander HR, Bartlett DL, Libutti SK.
Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver.
Oncologist. 5: 416-24, 2000. [Journal]
117)  Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD.
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Biochem Biophys Res Commun. 268: 183-91, 2000. [Journal]
118)  Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK.
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Microvasc Res. 60: 70-80, 2000. [Journal]
119)  Berger AC, Tang G, Alexander HR, Libutti SK.
Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis.
J Immunother. 23: 519-27, 2000. [Journal]
120)  Said B, McCart JA, Libutti SK, Choyke PL.
Ferumoxide-enhanced MRI in patients with colorectal cancer and rising CEA: surgical correlation in early recurrence.
Magn Reson Imaging. 18: 305-9, 2000. [Journal]
121)  Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, Skarulis MC, Gorden P.
Forty-eight-hour fast: the diagnostic test for insulinoma.
J Clin Endocrinol Metab. 85: 3222-6, 2000. [Journal]
122)  Kershaw MH, Westwood JA, Zhu Z, Witte L, Libutti SK, Hwu P.
Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature.
Hum Gene Ther. 11: 2445-52, 2000. [Journal]
123)  Mohr VH, Vortmeyer AO, Zhuang Z, Libutti SK, Walther MM, Choyke PL, Zbar B, Linehan WM, Lubensky IA.
Histopathology and molecular genetics of multiple cysts and microcystic (serous) adenomas of the pancreas in von Hippel-Lindau patients.
Am J Pathol. 157: 1615-21, 2000. [Journal]
124)  Bacharach SL, Libutti SK, Carrasquillo JA.
Measuring tumor blood flow with H(2)(15)O: practical considerations.
Nucl Med Biol. 27: 671-6, 2000. [Journal]
125)  Lodge MA, Carson RE, Carrasquillo JA, Whatley M, Libutti SK, Bacharach SL.
Parametric images of blood flow in oncology PET studies using [15O]water.
J Nucl Med. 41: 1784-92, 2000. [Journal]
126)  Feldman AL, Libutti SK.
Progress in antiangiogenic gene therapy of cancer.
Cancer. 89: 1181-94, 2000. [Journal]
127)  Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR, Libutti SK.
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Clin Cancer Res. 6: 4628-34, 2000. [Journal]
128)  Libutti SK, Barlett DL, Fraker DL, Alexander HR.
Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
J Am Coll Surg. 191: 519-530, 2000. [Journal]
129)  Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, Figg WD, Alexander HR, Libutti SK.
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.
J Surg Res. 91: 26-31, 2000. [Journal]
130)  Berger AC, Alexander HR, Wu PC, Tang G, Gnant MF, Mixon A, Turner ES, Libutti SK.
Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
Cytokine. 12: 992-1000, 2000. [Journal]
131)  Feingold DL, Alexander HR, Chen CC, Libutti SK, Shawker TH, Simonds WF, Marx SJ, Skarulis MC, Doppman JL, Schrump DS, Bartlett DL.
Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas.
Surgery. 128: 1103-9;discussion 1109-10, 2000. [Journal]
132)  Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL.
Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
Cancer Gene Ther. 7: 66-73, 2000. [Journal]
133)  Libutti S, Zeiger M, Mazzanti C, Umbrict C, inventor; DHHS, assignee.
Diagnostic tool for diagnosing benign versus malignant thyroid lesions.
Patent Pending, Filed in 2004. Application No. 11/547,995. Pending [Patent]
134)  Libutti S, Feldman A, inventor; DHHS, assignee.
Methods for treating tumors using anti-angiogenic compounds.
Patent Pending, Filed in 1999. Application No. 60/133,243. Pending [Patent]
135)  Libutti S, Kayton M, inventor; DHHS, assignee.
Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule.
Patent Pending, Filed in 2002. Application No. 10/510,652; 11/014,472. Pending [Patent]
136)  Stern D, Clauss M, Kao J, Kayton M, Libutti S, inventor.
Antibody which specifically binds to endothelial-monocyte activating polypeptide II.
US Patent: 5,641,867. 1997. [Patent]
137)  Stern D, Clauss M, Kao J, Kayton M, Libutti S, inventor.
Endothelial monocyte activating polypeptide II: a mediator which activates host response.
US Patent: 6,228,837. 2001. [Patent]
138)  Stern D, Clauss M, Kao J, Kayton M, Libutti S, inventor.
Endothelial monocyte activating polypeptide II: a mediator which activates host response.
US Patent: 6,734,168. 2004. [Patent]
139)  Bass L, Libutti S, Eaton A, inventor.
Tissue bonding and sealing composition and method of using the same.
US Patent: 5,209,776. 1993. [Patent]
140)  Bass L, Libutti S, Eaton A, inventor.
Tissue bonding and sealing composition and method of using the same.
US Patent: 5,292,362. 1994. [Patent]

This page was last updated on 11/25/2008.